The BREATHE study presented its first results at the 41st Congress of the Portuguese Society of Pulmonology and the 1st Ibero-American Congress of Pulmonology, held from November 27 to 30, 2025, in Algarve, Portugal. The results were presented through a commented poster entitled “Phenotypic and Clinical Characterization of Severe Asthma Patients: Insights from Biologic and Nonbiologic Therapy Groups”.
BREATHE aims to characterise the clinical, functional, and inflammatory profile of adults with severe asthma in Portugal, with a particular focus on the use of healthcare resources. The study analysed data from 214 patients enrolled in the RAG, comparing individuals receiving biologic therapies with those not yet treated with biologic.
Among the patients treated with biologics (46% of the cohort), the most frequently used therapies were anti-IL5 agents (57%), followed by dupilumab (21%), omalizumab (18.4%), and tezepelumab (3%). Importantly, while inflammatory and functional markers were broadly comparable between groups, patients receiving biologic therapies showed significantly lower healthcare utilisation, including fewer courses of oral corticosteroids and fewer emergency department visits. These findings highlight the potential impact of biologic treatments on disease control and healthcare burden in severe asthma.
The presentation of these results marks an important milestone for the BREATHE study, reinforcing the value of national registry-based research in advancing the understanding of severe asthma and supporting more personalised and effective treatment strategies.
